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Background:Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived
to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). However, current
data on MBC are largely derived from small case series or population-based reports. This study aimed to assess the
clinicopathological features and outcome of MBC identified through an international multicentre collaboration.
Methods: A large international multicentre series of MBC (no¼ 405) with histological confirmation and follow-up information has
been included in this study. The prognostic value of different variables and outcome has been assessed and compared with
grade, nodal status and ER/HER2 receptor-matched ductal/NST breast carcinoma.
Results: The outcome of MBC diagnosed in Asian countries was more favourable than those in Western countries. The outcome
of MBC is not different from matched ductal/NST carcinoma but the performance of the established prognostic variables in MBC
is different. Lymph node stage, lymphovascular invasion and histologic subtype are associated with outcome but tumour size and
grade are not. Chemotherapy was associated with longer survival, although this effect was limited to early-stage disease. In this
study no association between radiotherapy and outcome was identified. Multivariate analysis of MBC shows that histologic
subtype is an independent prognostic feature.
Conclusions: This study suggests that MBC is a heterogeneous disease. Although the outcome of MBC is not different to
matched conventional ductal/NST breast carcinoma, its behaviour is dependent on the particular subtype with spindle cell
carcinoma in particular has an aggressive biological behaviour. Management of patients with MBC should be based on validated
prognostic variables.
Mammary parenchymal cells show a high degree of phenotypic
plasticity, which is seen in both benign and malignant lesions
(Smith and Taylor 1969; Spagnolo and Shilkin 1983; Kaufman
et al, 1984; Wang et al, 2001; Rosen 2009; van Deurzen et al, 2011).
Conventional (ductal/no specific type) invasive breast carcinoma
occasionally shows minor components of metaplastic elements
with squamous and/or mesenchymal appearances (Kaufman et al,
1984). However, when the metaplastic components form a
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significant proportion (usually410%, although some authors have
used different cutoffs including o10% (Downs-Kelly et al, 2009),
X20% (Gwin et al, 2010) or X50% (Yamaguchi et al, 2010)) the
term metaplastic breast carcinoma (MBC) is used. Although MBC
is rare comprising 0.3%–1.5% of breast cancer, it is recognized to
be a heterogeneous group of tumours with multiple subtypes
reflecting variable histological appearances (Hennessy et al, 2006;
Tse et al, 2006; Pezzi et al, 2007; Yamaguchi et al, 2010; Tseng and
Martinez, 2011; Reis-Filho et al, 2012). There is a perception that
MBC is an aggressive tumour with poor outcome. This is mainly
based on previous studies of MBC that included either a limited
number of cases or a population-based database without
histological confirmation and with different clinical stages (i.e.,
stage I to IV (Hennessy et al, 2006)) and ethnicity (Foschini et al,
1993; Rayson et al, 1999; Hennessy et al, 2006; Tse et al, 2006;
Luini et al, 2007; Pezzi et al, 2007; Jung et al, 2010; Yamaguchi
et al, 2010; Bae et al, 2011; Tseng and Martinez 2011; Lee et al,
2012; Lester et al, 2012; Reis-Filho et al, 2012). In addition, some
molecular studies have shown some shared characteristics between
MBC and the aggressive high grade basal-like class of ductal
carcinoma (Reis-Filho et al, 2006). As a consequence, the outcome
and prognostic risk stratification of patients with MBC remain
uncertain. Clinicopathological variables that are well-validated in
conventional invasive breast carcinoma may behave differently in
MBC. Therefore, in this large international multicentre study of
MBC with histological confirmation and long-term follow-up, we
aimed to assess the prognostic value of the different clinicopatho-
logical variables and determine its outcome compared with grade,
node and receptor matched conventional invasive ductal carci-
noma of no special type.
MATERIALS AND METHODS
This study included three case series. The first series comprises
MBC diagnosed at and identified from the files of six institutions in
Europe including the United Kingdom (three institutions;
Nottingham, Leeds and Leicester), The Netherlands, Switzerland
and Spain (n¼ 313). The second series comprises MBC identified
from the files of three institutions from Asia including Singapore
and Hong Kong (two institutions; n¼ 92). These series consist of
cases diagnosed between 1991 and 2012. Cases were reviewed by a
consultant pathologist in each centre to confirm the initial
diagnosis and to assess the neoplastic cell phenotype/morphology.
Criteria for diagnosis of MBC were as previously published (Rosen,
2009; Reis-Filho et al, 2012). MBC was defined by the presence of
non-glandular epithelial (squamous) or mesenchymal (spindle or
matrix producing) elements associated with DCIS or conventional
mammary type invasive carcinoma. In the occasional cases lacking
a conventional carcinomatous element, the diagnosis was con-
firmed using immunohistochemical markers of epithelial differ-
entiation. MBC histologic subtypes included the following: spindle
(including sarcomatoid and pleomorphic), squamous, mixed
squamous and spindle and matrix producing types (Rosen, 2009;
Reis-Filho et al, 2012). Variables assessed and collected include
tumour histological subtype, proportion of each metaplastic
component, histological grade and its components (tubule
formation, pleomorphism and mitotic count), degree of cellularity,
presence and degree of tumour necrosis and presence, grade and
extent of associated ductal carcinoma in situ (DCIS). Clinico-
pathological characteristics including tumour size, total number of
lymph nodes and number of positive nodes, lymphovascular
invasion, hormone receptor and HER2 status were obtained from
the database whenever available. Clinical and outcome data
including menopausal status, treatment performed including local
(surgical and radiotherapy) and systemic therapy (endocrine
therapy and chemotherapy), development of local, regional and
distant recurrence and time to events, survival status, survival time
and cause of death were collected from patients’ notes. Breast
cancer-specific survival (BCSS) was defined as the interval between
the operation and death from (or with) breast cancer, death being
scored as an event, and patients who died from other causes or
were still alive were censored at the time of last follow-up (Rakha,
2013). Out of the 405 MBC, 41 cases were excluded as follows:
cases presented as metastatic (within 2 months of presentation;
n¼ 5), recurrent (n¼ 14) or contralateral (n¼ 4) breast cancer,
cases received neoadjuvant chemotherapy or conventional mam-
mary carcinoma withp10% metaplastic component (n¼ 18). The
clinicopathological features of the remaining 364 MBC are shown
in Table 1. Complete follow-up data of MBC after exclusion of
ineligible cases was available for 285 cases.
The third series is a control group (n¼ 285) of age, histological
grade, lymph node stage, oestrogen receptor (ER) and HER2
status matched conventional invasive ductal/NST primary
breast carcinomas identified from the well-defined Nottingham
primary operable (p5 cm) breast cancer series (n¼ 1950) that has
been described in previous publications (Rakha et al, 2007, 2008,
2009, 2011).
This study was approved by the Nottingham Research Ethics
Committee.
STATISTICAL ANALYSIS
Survival curves were produced using the Kaplan–Meier method
and were compared using log rank tests. Survival rates are
presented with their 95% confidence intervals. Multivariate
analyses were conducted using Cox proportional hazard regression
models. The clinicopathological variables were compared using
contingency tables and w2-tests. All comparisons were two-sided
and a p-value of o0.05 was considered significant.
RESULTS
All MBC patients were female, of whom 70% had axillary clearance
and 30% had lymph node (LN) sample or sentinel node biopsy.
Median LN number was 9 (range 1–46). Thirty percent showed
metastatic (positive) nodes that were mainly of low number
(median¼ 2). Forty-five percent of the positive nodes contained
deposits of metaplastic elements as either pure (25%) or mixed
with conventional carcinomas (20%), the remainder were involved
by conventional adenocarcinoma of ductal/NST type. Diagnosis of
MBC was based on the presence of non-glandular (squamous and/
or mesenchymal including matrix producing) differentiation
associated with conventional-type carcinomatous element
(o90%) that was identified in 57% of cases and/or DCIS that
was identified in 42% of cases (Table 1). More mixed spindle and
squamous (37%) and spindle (28%) presented at an advanced stage
(pT3&4) than squamous (21%) and matrix producing (18%)
carcinomas but this different was not significant (P¼ 0.17).
Of the whole series, 276 (76%) were fromWestern countries and
88 (24%) from Asian countries. There was a significant difference
between MBC diagnosed in Western countries and Asian countries
with frequent mastectomy and higher histological grade tumours
with more squamous and less spindle carcinoma subtypes in Asian
countries (Table 2).
Outcome analysis. During the period of follow-up (maximum 244
months, interquartile range 56), 65 patients developed recurrent
disease and 95 patients died (55 of BC and 40 of other causes). No
difference in the outcome was detected between recent (at or
after 2005) and old (before 2005) cases (X2¼ 0.08, P¼ 0.779).
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When cases were stratified based on the centre of diagnosis, a
significant difference in the outcome between centres was found
(X2¼ 21.35, P¼ 0.011). There was a significant difference in the
outcome between MBC diagnosed in Western countries and those
diagnosed in Asian countries (X2¼ 8.95, DF¼ 1, P¼ 0.003).
However, when locally advanced cases were excluded this
difference was no longer significant (X2¼ 2.71, DF¼ 1, P¼ 0.099
and Table 3). Figure 1 shows the outcome of MBC from Western
and Asian countries as compared with the control group.
Therefore, further analysis of prognostic markers in MBC was
performed with consideration to countries of origin (Western
versus Asian) and stage of the disease (with and without stage
pT3&4 tumours).
Prognostic markers in MBC. No association with outcome in
terms of BCSS and DFI was found in MBC regarding patients’ age,
menopausal status, histological grade; even when analysed as low and
high grade (grade 1/2 versus 3) or any of its components
(pleomorphism, mitosis or tubule formation) when analysed
separately. Similarly no association between outcome and the degree
of tumour cellularity, presence of tumour necrosis or coexistence of
conventional-type carcinoma or DCIS was found (P40.05).
There was a significant association between lymph node stage
(Figure 2A) and presence of lymphovascular invasion and BCSS
(X2¼ 15.8, DF¼ 2, Po0.0001 and X2¼ 7.6, DF¼ 2, P¼ 0.006,
respectively) but not with DFI. The same associations were
observed in the Western and Asian subgroups with or without
Table 2. Comparison between MBC diagnosed in the
Western countries and Asian countries
Western
series
Asian
series
P-value
Mean age in years (range) 61 (27–96) 57 (32–85) 0.017
Type of surgery
Breast conserving surgery 95 (50) 21 (24) o0.001
Mastectomy 96 (50) 67 (76)
Tumour Size
TNM pT1 46 (24) 16 (19) 0.797
TNM pT2 100 (52) 47 (55)
TNM pT3&4 45 (24) 22 (26)
Tumour subtypes
Spindle cell 95 (34) 21 (24) 0.001
Squamous 47 (17) 30 (34)
Mixed squamous and spindle 36 (13) 13 (15)
Matrix producing 80 (29) 24 (27)
Fibromatosis-likea 18 (7) 0 (0)
Associated conventional carcinoma
Yes 147 (58) 73 (88) o0.001
No 105 (42) 10 (12)
Invasive carcinoma grade
1 4 (1) 2 (2) 0.009
2 71 (26) 7 (10)
3 196 (73) 64 (88)
LN stage
1 (LN negative) 131 (73) 49 (68) 0.118
2 (1–3 positive nodes) 35 (19) 12 (16)
3 (43 positive nodes) 14 (8) 12 (16)
Lymphovascular invasion
Negative 150 (78) 68 (81) 0.596
Positive 42 (22) 16 (19)
Radiotherapy 123 (68) 30 (50) 0.038
Chemotherapy 114 (61) 28 (81) 0.022
aFibromatosis-like is a recently recognized subtype is a low grade spindle carcinoma
diagnosed mainly in Nottingham a part of a consultation service. Follow-up was available for
two cases only; therefore, they were grouped with spindle MBC.
Table 1. Clinicopathological features of metaplastic breast
carcinoma (n¼364)
Variables MBC
Time of diagnosisa
Before 2005 43%
At or after 2005 57%
Mean age in years (range) 60 (27–96)
Menopausal status
Pre/perimenopausal 32%
Postmenopausal 68%
Type of surgery
Breast conserving surgery 41%
Mastectomy 59%
Tumour Size
TNM pT1 23%
TNM pT2 53%
TNM pT3&4 24%
Focality
Localised 89%
Multifocal 11%
LN stage
1 (LN negative) 71%
2 (1–3 positive nodes) 19%
3 (43 positive nodes) 10%
Invasive carcinoma grade
1 2%
2 23%
3 75%
Mitotic counts
1 9%
2 19%
3 72%
Degree of nuclear pleomorphism
Mild 2%
Moderate 7%
Marked 91%
Associated conventional invasive carcinoma
Yes 57%
No 43%
Proportion of metaplastic elements
11%-50% 32%
51%-90% 24%
490% 44%
Degree of cellularity
High 59%
Intermediate 31%
Low 2%
Heterogeneous 8%
Associated DCIS
Yes 42%
No 58%
Lymphovascular invasion
Negative 79%
Positive 21%
Oestrogen receptor
Negative 93%
Positive 7%
Progesterone receptor
Negative 94%
Positive 6%
HER2
Negative 99%
Positive 1%
Radiotherapy 69%
Chemotherapy 65%
Abbreviations: DCIS¼ductal carcinoma in situ; MBC¼metaplastic breast carcinoma.
aCases were split at 2005 based on the number of cases, time of diagnosis and the length of
follow-up period.
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inclusion of locally advanced (pT3&4) cases. TNM pT stage was
correlated with outcome (X2¼ 10.3, P¼ 0.006 and X2¼ 11.5,
P¼ 0.003 for BCSS and DFI, respectively); however, when pT3&4
cases were excluded, these associations were no longer significant.
There was an association between MBC histologic subtypes and
BCSS and DFI (X2¼ 13.9, P¼ 0.008 and X2¼ 6.7, P¼ 0.01,
respectively). The difference in the outcome between matrix
producing and squamous carcinomas was significant and both
were associated with a better prognosis while spindle and mixed
spindle and squamous were associated with the worst prognosis
and their outcome was not statistically different (Figure 3). These
associations were maintained after exclusion of locally advanced
cases (X2¼ 7.4, P¼ 0.006 and X2¼ 6.2, P¼ 0.01 for BCSS and DFI,
respectively). Chemotherapy was associated with longer survival
(X2¼ 4.1, P¼ 0.045) but, when locally advanced cases were
excluded, this association lost its significance. No associations
between radiotherapy and outcome were found. Table 4 shows
multivariate cox regression analysis of MBC with and without
locally advanced cases. This indicates that MBC subtype is an
independent prognostic variable associated with BCSS and DFI.
DISCUSSION
Metaplastic carcinoma of the breast (MCB) remains as a poorly
characterised subtype of breast cancer. Although MBC is rare, its
recognition as a discrete entity is increasing (Pezzi et al, 2007;
Tseng and Martinez, 2011; Lee et al, 2012). Most of the prognostic
studies of MBC have been small and with conflicting results or
included non-validated cases from population based databases
(Foschini et al, 1993; Rayson et al, 1999; Hennessy et al, 2006; Tse
et al, 2006; Luini et al, 2007; Pezzi et al, 2007; Jung et al, 2010;
Yamaguchi et al, 2010; Bae et al, 2011; Tseng and Martinez 2011;
Lee et al, 2012; Lester et al, 2012; Reis-Filho et al, 2012). In this
large international multicentre series of histologically confirmed
cases of MBC we have critically assessed the prognostic value of
known prognostic variables and determine the outcome in
comparison with matched conventional breast carcinoma of
ductal/no specific type.
This study identified some factors that may explain the
conflicting data published to date regarding clinicopathological
and outcome data. MBC diagnosed in Asian countries showed
longer survival compared with those diagnosed in Western
countries. This can be partly explained by the over-representation
of locally advanced cases in Western countries, other epidemio-
logical factors or environmental determinants akin to those
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Figure 1. Correlation between MBC diagnosed in Western and Asian
countries and outcome. (A) Comparison of breast cancer-specific
survival (BCSS) of patients with metaplastic breast carcinoma
diagnosed Asian countries (upper green curve; 88 patients) and
Western countries (lower blue curve; 197 patients) as compared with
the control group of conventional ductal carcinoma (middle grey curve;
285 patients) (X2¼12.1, DF¼2, P¼ 0.002). (B) Comparison of BCSS of
same groups after exclusion of locally advanced cases (tumours4stage
T2); Asian patients (upper green curve; 63 patients) and Western
patients (lower blue curve; 145 patients as compared with the control
group of conventional ductal carcinoma (middle grey curve; 285
patients) (X2¼2.9, DF¼ 2, P¼ 0.237). A full color version of this figure
is available at the British Journal of Cancer journal online.
Table 3. Cumulative survival of metaplastic carcinoma
(including western and Asian subgroups) after exclusion of
advanced-stage cases compared with early-stage
conventional NST carcinoma
Interval
start time
in months
Number of
patients
entering
interval
Number
exposed to
risk
Cumulative
proportion
surviving at
end of interval
MBC
30 285 242 0.85
60 162 137 0.77
90 98 78 0.74
120 54 46 0.72
150 35 27 0.67
Western
30 145 122 0.88
60 84 70 0.78
90 48 36 0.76
120 23 20 0.72
150 15 11 0.59
Asian
30 63 53 0.96
60 40 36 0.85
90 27 22 0.85
120 16 14 0.85
150 10 8 0.85
IDC NST
30 284 282 0.91
60 254 254 0.80
90 222 210 0.76
120 188 169 0.74
150 144 116 0.71
Abbreviations: IDC NST¼ invasive ductal carcinoma of no special type; MBC¼metaplastic
breast carcinoma.
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observed in the stomach and upper gastrointestinal cancer (Gill
et al, 2003). Other factors may include differences in treatment
protocols. In this study, mastectomy rates and systemic chemo-
therapy use were higher in the Asian series.
The over-representation of metastatic advanced and locally
advanced cases in some series may be one of the reasons for the
reported poor outcome of MBS as the outcome in our series
improved when these cases were excluded. Outcome analysis
revealed that MBC is associated with shorter survival compared
with matched conventional carcinoma. However, when analysis
was restricted to early-stage cases (pT1&2) the outcome was not
different to stage matched conventional carcinoma. Consistent
with our findings, some authors have reported that, although MBC
is associated with poor prognostic indicators, its outcome is
comparable to matched conventional breast carcinomas (Beatty
et al, 2006). When known prognostic variables in conventional
breast carcinoma were analysed in the context of MBC, we found
that lymph node stage and lymphovascular invasion were
significant predictors of outcome. However, no association
between histological grade or its components (mitosis, tubule
formation and pleomorphism) (Rakha et al, 2008) or the Trojani
grading system of sarcoma (mitosis, necrosis and differentiation)
(Trojani et al, 1984) and outcome was detected. A finding that may
represent the nature of the tumour with transdifferentiation of the
malignant epithelial mammary tissue to a different histologic type.
Tumour size also was not a significant prognostic factor.
One key observation in the current study is that the different
subtypes of MBC are associated with distinct outcome. In this
series, matrix producing carcinoma was associated with the best
outcome while spindle and mixed spindle and squamous
carcinomas were associated with the worst outcome and this was
an independent prognostic variable (Beatty et al, 2006; Nayak et al,
2013). The better outcome of matrix producing carcinoma
compared with other subtypes of MBC may be a reflection of its
smaller primary tumour size and less frequent nodal metastasis and
lymphovascular invasion (data not shown). In this study, it
should be noted that few cases of fibromatosis-like metaplastic
carcinoma with linked outcome data were included and no
low-grade adenosquamous subtypes, which we consider as a
distinct entity, were included in this study. Both of these subtypes
are recognized to have an excellent outcome (Van Hoeven et al,
1993; Gobbi et al, 1999).
Chemotherapy was associated with better outcome, although the
effect was limited in early stage cases. Some authors have reported
that systemic therapy may be less effective in MBC (Rayson et al,
1999; Gibson et al, 2005). In this study no association between
radiotherapy and outcome was identified. Although Tseng and
Martinez (2011) reported that radiotherapy is associated with
improved overall survival I MBC, they included historical cases
diagnosed from 1988 in their analysis and only 39% received
RT with apparent low 10-year survival (53%). The effect of
chemotherapy and radiotherapy on the outcome is best assessed in
a focused randomized clinical trial.
This study has limitations. It is a retrospective study with the
possibility of selection bias. Although the histological diagnosis of
MBC was reviewed by breast pathologists, this was carried out
locally in each institution with no central pathology review.
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Figure 3. Association between MBC histologic subtype and outcome.
(A) Association between breast cancer-specific survival and MBC
histologic subtypes (matrix producing carcinoma (77 cases; upper
purple), squamous (74 patients; upper middle green), mixed squamous
and spindle (41 patients; lower middle grey) and spindle carcinoma (91
patients; lower blue) (X2¼13.9, DF¼ 3, P¼0.008). (B) Association
between breast cancer-specific survival and MBC histologic subtype
analysed as two groups (upper green; matrix producing and squamous
combined (151 cases) and lower blue; spindle and mixed spindle and
squamous (132 patients); X2¼10.8, DF¼1, P¼ 0.001). A full color
version of this figure is available at the British Journal of Cancer journal
online.
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Figure 2. Association between lymph node stage in MBC and breast
cancer-specific survival (node negative (180 patients)¼ upper blue,
node positive 1–3 (46 patients)¼middle green and node positive43
(26 patients)¼ lower grey) (X2¼15.8, DF¼2, Po0.0001). The same
association was observed in Western and Asian subgroups with or
without inclusion of locally advanced cases. A full color version of this
figure is available at the British Journal of Cancer journal online.
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In conclusion, this study provides evidence-based data that
MBC is a heterogeneous disease encompassing biologically
different tumour classes with variable outcome. Although the
behaviour of MBC overall is not different to matched conventional
forms of ductal/NST invasive breast carcinoma, the pattern of
relevant prognostic variables in MBC is different from the
spectrum of well-established variables in conventional breast
carcinoma. Tumour histological subtype of MBC provides
independent prognostic information. Both observations should
be considered when managing MBC patients.
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